TORONTO (August 26, 2019) – Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that the human factors evaluation (“HFE”) required to support its planned Investigational Device Exemption (“IDE”) […]
TORONTO (August 6, 2019) – Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces the successful completion of the chronic procedures performed under Good Laboratory Practice (“GLP”) principles using […]
TORONTO (July 31, 2019) – Titan Medical Inc. (TSX: TMD) (NASDAQ: TMDI) (“Titan” or “the Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces financial results for the three and six months ended June 30, 2019. All financial results are […]
Dear Titan Medical Shareholders, It is my pleasure to provide this mid-year update on Titan Medical’s progress and to share with you our outlook for the remainder of the year. The first half of 2019 has been very busy and productive. Our dedicated management team, consultants and product development partners have been relentlessly executing on […]
TORONTO (July 18, 2019) – Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that all procedures under Good Laboratory Practice (“GLP”) principles associated with the acute and chronic […]